Home Cart Sign in  
Chemical Structure| 95-25-0 Chemical Structure| 95-25-0

Structure of Chlorzoxazone
CAS No.: 95-25-0

Chemical Structure| 95-25-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Chlorzoxazone, a potassium channel activator, is a centrally acting muscle relaxant used to treat muscle spasm and the resulting pain or discomfort. It is also a CYP2E1 inhibitor with IC50 value of 1.03μM.

Synonyms: NSC 26189

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Chlorzoxazone

CAS No. :95-25-0
Formula : C7H4ClNO2
M.W : 169.57
SMILES Code : O=C1OC2=CC=C(Cl)C=C2N1
Synonyms :
NSC 26189
MDL No. :MFCD00005717
InChI Key :TZFWDZFKRBELIQ-UHFFFAOYSA-N
Pubchem ID :2733

Safety of Chlorzoxazone

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P264-P270-P280-P301+P312+P330-P302+P352+P332+P313+P362+P364-P305+P351+P338+P337+P313-P501

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Peripheral blood mononuclear cells 10 μM 48 h Inhibit T cell activation and proliferation Cell Death Dis. 2020 Mar 2;11(3):158
Human umbilical cord mesenchymal stem cells 2-20 μM 24 h Enhance the immunosuppressive capacity of MSCs, inhibit T cell activation and proliferation Cell Death Dis. 2020 Mar 2;11(3):158
Purkinje neurons 5 µM No significant effect on spike regularity or firing frequency in Atxn1154Q/2Q Purkinje neurons Mov Disord. 2021 Mar;36(3):622-631
Purkinje neurons 10 µM Improved spike regularity in Atxn1154Q/2Q Purkinje neurons without affecting firing frequency Mov Disord. 2021 Mar;36(3):622-631
Purkinje neurons 50 µM Improved spike regularity in Atxn1154Q/2Q Purkinje neurons but greatly suppressed firing frequency Mov Disord. 2021 Mar;36(3):622-631
cerebellar Purkinje cells (PCs) 30 μM 5 min To study the effect of CHZ-FA combination on the firing frequency and variability of PCs in SCA3-84Q mice. Results showed that the CHZ-FA combination restored the firing precision of SCA3-84Q PCs without affecting their firing rate. Hum Mol Genet. 2024 Aug 6;33(16):1406-1419

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Transgenic mice SCA2-58Q transgenic mice Intraperitoneal injection 30 mg/kg Twice a week, from 2 to 11 months of age Long-term i.p. injections of CHZ restored the precision of spontaneous pacemaking activity in Purkinje cells of SCA2-58Q mice and alleviated age-dependent motor impairment. Cell Calcium. 2021 Jan;93:102319
Mice SCA3-84Q mouse model Intraperitoneal injection 30 mg/kg 5 days per week for 6 weeks To study the effect of CHZ-FA combination on motor coordination, anxiety, memory, and depression in SCA3-84Q mice. Results showed that the CHZ-FA combination significantly improved motor coordination, anxiety behavior, recognition memory, and depressive-like behavior in SCA3-84Q mice. Hum Mol Genet. 2024 Aug 6;33(16):1406-1419
Rats Intermittent access to alcohol (IAA) and continuous access to alcohol (CAA) models Intraperitoneal injection 0, 10, 30, or 50 mg/kg Once per week, for 3 hours CZX significantly and dose-dependently reduced alcohol intake in IAA rats but not in CAA rats. CZX also reduced alcohol preference in IAA rats and decreased the tendency for rapid initial alcohol consumption in IAA rats. Biol Psychiatry. 2011 Apr 1;69(7):618-24

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02654236 Alcohol Consumption Not Applicable Recruiting July 2019 United States, Indiana ... More >> Indiana University Recruiting Indianapolis, Indiana, United States, 46202 Contact: Jennifer Lehman, RN    317-278-1872    jgeck@iu.edu    Contact: Megan Comerford, BS, MPH    3172789226    mcomerfo@iu.edu    Sub-Investigator: Naga Chalasani, MD          Principal Investigator: Suthat Liangpunsakul, MD          Sub-Investigator: David Crabb, MD Less <<
NCT02291666 Type 2 Diabetes Phase 4 Recruiting October 2019 Canada, Quebec ... More >> Centre hospitalier de l'Université de Montréal (CHUM) Recruiting Montreal, Quebec, Canada, H2X0A9 Contact: Veronique Michaud, BPharm, PhD    514-8908000 ext 15812    v.michaud@umontreal.ca    Contact: Jacques Turgeon, BPharm,PhD    514-8908045    jacques.turgeon@umontreal.ca    Principal Investigator: Veronique Michaud, BPharm,PhD          Sub-Investigator: Jean-Louis Chiasson, MD          Sub-Investigator: Jacques Turgeon, BPharm,PhD Less <<
NCT00340535 - Completed - United States, Pennsylvania ... More >> University of Pittsburgh Pittsburgh, Pennsylvania, United States, 15261 Less <<
NCT03103568 Drug Drug Interaction Phase 1 Completed - Germany ... More >> PAREXEL EPCU Berlin Berlin, Germany, 14050 Less <<
NCT00330434 Alcohol Drinking ... More >> Depression Smoking Cessation Attention Deficit Disorder Less << Not Applicable Completed - United States, Massachusetts ... More >> Tufts University School of Medicine Boston, Massachusetts, United States, 02111 Less <<
NCT01187862 Cytochrome Ph... More >>armacokinetics Less << Phase 1 Completed - Switzerland ... More >> University Hospital Basel, Switzerland, 4031 Less <<
NCT00138684 Insulin Resistance ... More >> Iron Overload Less << Phase 2 Completed - France ... More >> CHU Nantes Nantes, France Unité d'Investigation Clinique - Hôpital Pontchaillou Rennes, France, 35033 Less <<
NCT03563287 Obesity, Morbid ... More >> Bariatric Surgery Candidate Less << Not Applicable Completed - Finland ... More >> University of Eastern Finland Kuopio, Finland Less <<
NCT02405104 Osteoarthritis of Hip ... More >> Osteoarthritis, Knee Less << Phase 4 Active, not recruiting May 2019 Denmark ... More >> Northern Orthopaedic Division, Clinik Farsoe, Aalborg University Hospital Farsoe, Northern Jutland, Denmark Less <<
NCT01342341 - Completed - -
NCT01933542 Chlorzoxazone ... More >> Postoperative Pain Less << Phase 4 Completed - Denmark ... More >> Glostrup University Hospital Glostrup, Denmark, 2600 Less <<
NCT01342341 Alcohol Abuse Phase 4 Completed - United States, California ... More >> Ernest Gallo Clinic and Research Center Emeryville, California, United States, 94608 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

5.90mL

1.18mL

0.59mL

29.49mL

5.90mL

2.95mL

58.97mL

11.79mL

5.90mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories